메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
저널정보
한국생명윤리학회 생명윤리 생명윤리 제3권 제2호
발행연도
2002.12
수록면
54 - 60 (7page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색
질문

초록· 키워드

오류제보하기
Growth hormone(GH) therapy for children with GH deficiency enhances the growth, Mass production of recombinant DNA growth hormone has made GH therapy widely available for short children with no GH deficiency. Is it morally appropriate to enhance of the growth, by means of medical treatment, of a child with idiopathic short stature?
Of course, GH therapy is medically and ethically acceptable for children (1) with classic GH deficiency, (2) children with chronic renal failure who are waiting for kidney transplantation, (3) girls with Turner's syndrome.
However, children with a constitutional delay in growth must not be treated with GH. They instead need behavioral therapy and psychologic therapy.
With regard to normal, short children, some have argued that fairness requires us to offer GH therapy to the children whose predicted height is viewed as handicapping, or who are as psychologically disadvantaged as GH deficiency children. But the study demonstrates that there is no significant psychological benefits from GH therapy, and this raises skepticism about the effectiveness of GH therapy for normal, short children.
The principle of beneficence requires that GH therapy is morally justified only if the benefits from GH therapy would reasonably exceed the risk that GH therapy would cause to the normal, short children.

목차

1. 들어가는 말
2. 어떤 아이들에게 GH 치료를 시행할 것인가?
3. 결론
ABSTRACT

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

이 논문과 함께 이용한 논문

최근 본 자료

전체보기

댓글(0)

0

UCI(KEPA) : I410-ECN-0101-2010-570-002601810